<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="prp270096" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="pmc-domain-id">2563</journal-id><journal-id journal-id-type="pmc-domain">pharmrespersp</journal-id><journal-id journal-id-type="publisher-id">PRP2</journal-id><journal-title-group><journal-title>Pharmacology Research &amp; Perspectives</journal-title></journal-title-group><issn pub-type="epub">2052-1707</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12001268</article-id><article-id pub-id-type="pmcid-ver">PMC12001268.1</article-id><article-id pub-id-type="pmcaid">12001268</article-id><article-id pub-id-type="pmcaiid">12001268</article-id><article-id pub-id-type="pmid">40237398</article-id><article-id pub-id-type="doi">10.1002/prp2.70096</article-id><article-id pub-id-type="publisher-id">PRP270096</article-id><article-id pub-id-type="other">PRP2-2024-08-0284.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>In Vitro Structure&#8211;Activity Relationship Stability Study of Antisense Oligonucleotide Therapeutics Using Biological Matrices and Nucleases</article-title></title-group><contrib-group><contrib id="prp270096-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Lovri&#263;</surname><given-names initials="J">Jelena</given-names></name><xref rid="prp270096-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>jelena.lovric@astrazeneca.com</email></address></contrib><contrib id="prp270096-cr-0002" contrib-type="author"><name name-style="western"><surname>Yan</surname><given-names initials="J">Jingjing</given-names></name><xref rid="prp270096-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270096-cr-0003" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="X">XueQing</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4751-9726</contrib-id><xref rid="prp270096-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270096-cr-0004" contrib-type="author"><name name-style="western"><surname>Karlsborn</surname><given-names initials="T">Tony</given-names></name><xref rid="prp270096-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270096-cr-0005" contrib-type="author"><name name-style="western"><surname>Bood</surname><given-names initials="M">Mattias</given-names></name><xref rid="prp270096-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="prp270096-cr-0006" contrib-type="author"><name name-style="western"><surname>Dahl&#233;n</surname><given-names initials="A">Anders</given-names></name><xref rid="prp270096-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="prp270096-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Hilgendorf</surname><given-names initials="C">Constanze</given-names></name><xref rid="prp270096-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>constanze.hilgendorf@astrazeneca.com</email></address></contrib><contrib id="prp270096-cr-0008" contrib-type="author"><name name-style="western"><surname>Bhatt</surname><given-names initials="DK">Deepak Kumar</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9506-3757</contrib-id><xref rid="prp270096-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="prp270096-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D</named-content>
<institution>AstraZeneca</institution>
<city>Gothenburg</city>
<country country="SE">Sweden</country>
</aff><aff id="prp270096-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Cell, Gene and RNA Therapeutics, Discovery Sciences, BioPharmaceuticals R&amp;D</named-content>
<institution>AstraZeneca</institution>
<city>Gothenburg</city>
<country country="SE">Sweden</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Jelena Lovri&#263; (<email>jelena.lovric@astrazeneca.com</email>)<break/>
Constanze Hilgendorf (<email>constanze.hilgendorf@astrazeneca.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>13</volume><issue seq="30">3</issue><issue-id pub-id-type="pmc-issue-id">486727</issue-id><issue-id pub-id-type="doi">10.1002/prp2.v13.3</issue-id><elocation-id>e70096</elocation-id><history><date date-type="rev-recd"><day>29</day><month>11</month><year>2024</year></date><date date-type="received"><day>14</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>17</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-19 07:25:54.297"><day>19</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 AstraZeneca R&amp;D. <italic toggle="yes">Pharmacology Research &amp; Perspectives</italic> published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PRP2-13-e70096.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PRP2-13-e70096.pdf"/><abstract><title>ABSTRACT</title><p>The primary degradation pathway for antisense oligonucleotides (ASOs) involves endonuclease and exonuclease&#8208;mediated breakdown. The effect of various chemical modifications on the stability of oligonucleotides has not been systematically investigated. The aim of this study was to develop in&#160;vitro assays to predict in&#160;vivo metabolism of ASOs. Stability studies of ASOs with varying phosphorothioate/phosphodiester (PS/PO) content were conducted using nucleolytic matrices (snake venom 3&#8242;&#8208;exonuclease phosphodiesterase I [PDEI], mouse serum, and mouse liver homogenate) and analyzed by gel electrophoresis and liquid chromatography with ultraviolet and mass spectrometry detection (LC&#8208;UV/MS). Both sequence composition and backbone chemistry play important roles in influencing the stability of ASOs. Nucleolytic sensitivity observed with PDEI and mouse serum shows that ASOs with one PO modification in the backbone have higher stability than ASOs having two or three PO links, and with a lower PO content, the sequence has a larger influence on stability. Furthermore, the impact of a 5&#8208;methylcytidine nucleoside (<sup>Me</sup>C) on stability was observed. When the PO link was located after <sup>Me</sup>C (from 3&#8242; end), resistance toward nuclease hydrolysis increased, while the PO modification being before <sup>Me</sup>C had no protective effect. Employing nucleases and comparing stability data with matrices of animal origin holds promise for a future fast&#8208;track assessment of drug stability, enabling the efficient selection of optimal drug candidates for subsequent in&#160;vivo studies.</p></abstract><abstract abstract-type="graphical"><p>
<boxed-text position="anchor" content-type="graphic" id="prp270096-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PRP2-13-e70096-g004.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="prp270096-kwd-0001">ASO</kwd><kwd id="prp270096-kwd-0002">metabolic stability</kwd><kwd id="prp270096-kwd-0003">nuclease</kwd></kwd-group><counts><fig-count count="7"/><table-count count="2"/><page-count count="11"/><word-count count="7900"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:16.04.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="prp270096-ntgp-0001"><fn fn-type="funding" id="prp270096-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="prp270096-body-0001"><def-list list-content="abbreviations" id="prp270096-dl-0001"><title>Abbreviations</title><def-item><term id="prp270096-li-0001">3R</term><def id="prp270096-li-0002"><p>replace, reduce, refine</p></def></def-item><def-item><term id="prp270096-li-0003">ADME</term><def id="prp270096-li-0004"><p>absorption, distribution, metabolism, and excretion</p></def></def-item><def-item><term id="prp270096-li-0005">ASO</term><def id="prp270096-li-0006"><p>antisense oligonucleotide</p></def></def-item><def-item><term id="prp270096-li-0007">LNA</term><def id="prp270096-li-0008"><p>locked nucleic acid</p></def></def-item><def-item><term id="prp270096-li-0009">
<italic toggle="yes">m/z</italic>
</term><def id="prp270096-li-0010"><p>mass&#8208;to&#8208;charge ratio</p></def></def-item><def-item><term id="prp270096-li-0011">
<sup>Me</sup>C</term><def id="prp270096-li-0012"><p>5&#8208;methylcytidine</p></def></def-item><def-item><term id="prp270096-li-0013">MetID</term><def id="prp270096-li-0014"><p>metabolite identification</p></def></def-item><def-item><term id="prp270096-li-0015">PDEI</term><def id="prp270096-li-0016"><p>phosphodiesterase I</p></def></def-item><def-item><term id="prp270096-li-0017">PK</term><def id="prp270096-li-0018"><p>pharmacokinetics</p></def></def-item><def-item><term id="prp270096-li-0019">PO</term><def id="prp270096-li-0020"><p>phosphodiester</p></def></def-item><def-item><term id="prp270096-li-0021">PS</term><def id="prp270096-li-0022"><p>phosphorothioate</p></def></def-item><def-item><term id="prp270096-li-0023">SPE</term><def id="prp270096-li-0024"><p>solid&#8208;phase extraction</p></def></def-item><def-item><term id="prp270096-li-0025">UPLC&#8211;MS</term><def id="prp270096-li-0026"><p>ultra&#8208;performance liquid chromatography mass spectrometry</p></def></def-item></def-list><sec id="prp270096-sec-0001"><label>1</label><title>Introduction</title><p>ASO molecules are single&#8208;stranded nucleic acids consisting of approximately 15&#8211;30 nucleotides. They regulate gene expression through various mechanisms. Since the 1960s and 1970s, extensive research has been conducted to establish practical applications of ASOs [<xref rid="prp270096-bib-0001" ref-type="bibr">1</xref>, <xref rid="prp270096-bib-0002" ref-type="bibr">2</xref>, <xref rid="prp270096-bib-0003" ref-type="bibr">3</xref>]. Today, ASOs have emerged as a new class of therapeutic modalities with 10 drugs approved by the US Food and Drug Administration [<xref rid="prp270096-bib-0004" ref-type="bibr">4</xref>]. There are two major categories of ASOs, steric block and RNase H1 competent. The latter category comprises DNA/RNA mimic hybrid ASOs, which possess the unique ability to hybridize with RNA molecules. Through their interaction with the RNase H1 enzyme, they facilitate degradation of RNA, leading to a selective inhibition of gene expression at the sequence level [<xref rid="prp270096-bib-0005" ref-type="bibr">5</xref>, <xref rid="prp270096-bib-0006" ref-type="bibr">6</xref>].</p><p>Susceptibility to degradation by extra&#8208; and intracellular nucleases is a major challenge for delivering unmodified phosphodiester ASO therapeutics and achieving target engagement. It is well&#8208;known that unmodified oligonucleotides can degrade rapidly in biological matrices such as serum or living cells, with half&#8208;lives of 5&#8211;30&#8201;min [<xref rid="prp270096-bib-0007" ref-type="bibr">7</xref>, <xref rid="prp270096-bib-0008" ref-type="bibr">8</xref>, <xref rid="prp270096-bib-0009" ref-type="bibr">9</xref>, <xref rid="prp270096-bib-0010" ref-type="bibr">10</xref>]. Chemical modifications including nucleic acid backbone (1.0 generation), ribose sugar (2.0 generation), or nucleobase alternations (3.0 generation) [<xref rid="prp270096-bib-0011" ref-type="bibr">11</xref>] have been crucial in enhancing oligonucleotide stability. Introducing a sulfur atom in place of the non&#8208;bridging oxygen atom in the phosphate backbone has led to ASOs with a phosphothioate (PS) backbone [<xref rid="prp270096-bib-0012" ref-type="bibr">12</xref>], resulting in improved stability against nucleases, increased binding affinity to proteins, improved pharmacokinetic (PK) properties, and enhanced cellular uptake [<xref rid="prp270096-bib-0013" ref-type="bibr">13</xref>]. However, using a PS backbone in ASOs often led to reduced target affinity [<xref rid="prp270096-bib-0014" ref-type="bibr">14</xref>], which is addressed by further chemically modifying ribose sugars with bridged nucleic acids (BNAs) such as locked nucleic acids (LNA) [<xref rid="prp270096-bib-0015" ref-type="bibr">15</xref>] or 2&#8242;,4&#8242;&#8208;constrained 2&#8242;&#8208;<italic toggle="yes">O</italic>&#8208;ethyl bridged nucleic acids [<xref rid="prp270096-bib-0016" ref-type="bibr">16</xref>]. Additionally, the development of &#8220;gapmer&#8221; ASOs, combining the advantages of a PS backbone and BNAs, has been crucial in promoting stability and maintaining target affinity [<xref rid="prp270096-bib-0015" ref-type="bibr">15</xref>].</p><p>PS&#8208;modified ASOs have been associated with adverse effects such as inflammation, hepatotoxicity, and thrombocytopenia [<xref rid="prp270096-bib-0017" ref-type="bibr">17</xref>, <xref rid="prp270096-bib-0018" ref-type="bibr">18</xref>]. The introduction of LNAs in the flanking regions of gapmer ASOs led to a reduction in immunostimulatory response, higher potency, and improved binding affinities; however, it has also been linked to hepatic injury [<xref rid="prp270096-bib-0019" ref-type="bibr">19</xref>]. To mitigate these toxicities, introducing some PO linkages at the wings of a PS&#8208;ASO has shown promise in reducing toxicity, possibly by altering ASO interactions with certain immune&#8208;modulatory proteins [<xref rid="prp270096-bib-0018" ref-type="bibr">18</xref>]. Furthermore, to reduce retention of PS&#8208;ASOs within organs and to modulate the duration of gene silencing, a PS/PO mixed backbone can be used to adapt stability toward nucleases [<xref rid="prp270096-bib-0020" ref-type="bibr">20</xref>].</p><p>Metabolism of ASOs differs from the typical metabolic pathways of small molecules by not engaging cytochrome P450 (CYP) enzymes. Instead, their primary metabolic pathway involves degradation by nucleases, employing both endo&#8208; and exonucleases. Studies have revealed that ASOs degrade in&#160;vivo through initial endonuclease cleavage followed by exonuclease&#8208;driven hydrolysis [<xref rid="prp270096-bib-0004" ref-type="bibr">4</xref>]. However, in&#160;vitro studies have reported that ASO metabolism is driven by the activity of 3&#8242;&#8208;exonucleases rather than 5&#8242;&#8208;exonucleases and endonucleases [<xref rid="prp270096-bib-0021" ref-type="bibr">21</xref>].</p><p>In this study, a gapmer design of ASOs with varied PO and PS compositions, along with two different oligonucleotide sequences, was systematically investigated. The primary goal was to develop in&#160;vitro assays to predict ASO metabolism and systematically elucidate the contribution of the PS backbone to enhanced ASO stability. Our approach involved the application of gel electrophoresis and LC&#8208;UV/MS techniques to study the nucleolytic degradation of selected ASOs in the presence of nucleases or biological matrices, such as mouse serum and mouse liver homogenate. Additionally, metabolite identification (MetID) of selected ASO compounds using high&#8208;resolution mass spectrometry (HRMS) enabled a comparative analysis of metabolite profiles across different biological matrices. This comprehensive study sheds light on crucial insights into ASO metabolism and stability, paving the way for advancements in the development of more effective and safer ASO therapeutics.</p></sec><sec sec-type="materials-and-methods" id="prp270096-sec-0002"><label>2</label><title>Materials and Methods</title><sec id="prp270096-sec-0003"><label>2.1</label><title>Chemicals and Reagents</title><p>Nuclease&#8208;free water (Molecular Biology Reagent), magnesium chloride hexahydrate (for analysis EMSURE ACS, ISO, Reag. Ph Eur), ammonium acetate (NH<sub>4</sub>OAc, ACS reagent, &#8805;&#8201;97%), ammonium bicarbonate (Reagent Plus, &#8805;&#8201;99%), tris(hydroxymethyl)aminomethane (pro analysis, ACS, Reag. Ph Eur), guanidine hydrochloride (for molecular biology, &#8805;&#8201;99%), guanidine hydrochloride solution 6&#8201;M, Tris(2&#8208;carboxyethyl)phosphine hydrochloride (TCEP&#8208;HCl, bio&#8208;ultra, &#8805;&#8201;98%), <sc>l</sc>&#8208;cysteine (&#8805;&#8201;98%), ammonium hydroxide solution (ACS reagent, 28.0%&#8211;30.0% NH<sub>3</sub> basis), Tergitol, triethylamine (TEA, &#8805;&#8201;99.5%), and tetrahydrofuran (THF, anhydrous, contained 250&#8201;ppm BHT, &gt;&#8201;99.9%) were purchased from Merck Life Science (Solna, Sweden). Sodium acetate anhydrous (NaOAc, puris p.a., &#8805;&#8201;99%), acetonitrile (ACN, Optima LC/MS grade), methanol (Optima LC/MS grade), sodium chloride (&#8805;&#8201;95.5%), TBE buffer (tris&#8208;borate&#8208;EDTA, 10X, Thermo Scientific), Hi&#8208;density TBE sample buffer (5X), and TBE gels, 10% (both Invitrogen Novex), Tissue &amp; Cell Lysis Solution (LGC Biosearch Technologies, Hoddeson, UK, cat. no. MTC096H) were obtained from Thermo Fisher (Stockholm, Sweden). 1,1,1,3,3,3&#8208;hexafluoro&#8208;2&#8208;propanol (HFIP, &gt;&#8201;99%) from TCI was ordered from Chemtronica (Sollentuna, Sweden). Proteinase K (20&#8201;mg/mL, cat. no. 19133) was obtained from Qiagen (Kista, Sweden) while ethidium bromide (10&#8201;mg/mL) was purchased from VWR (Stockholm, Sweden). Ultrapure water from Millipore Sigma (Merck KGaA, Burlington, MA, USA) was used for the preparation of all aqueous solutions. Clarity OTX 25&#8201;mg/well SPE plates were purchased from Phenomenex (V&#230;rl&#248;se, Denmark) while Evolute Oligo 1, 30&#8201;mg SPE plates were obtained from Biotage (manufacturing batch number: 654&#8208;2&#8208;03, Uppsala, Sweden). Pooled mouse serum (C57BL/6 strain) was purchased from Merck Life Science (catalogue number: M5905, source number: SLCQ4598, Solna, Sweden) and Envigo (code: S.R.&#8208;0135, batch: 22&#8208;1094, Indianapolis, IN, USA).</p></sec><sec id="prp270096-sec-0004"><label>2.2</label><title>Oligonucleotides Used in the Study</title><p>Four oligonucleotides were selected for initial stability studies against PDEI, as shown in Table&#160;<xref rid="prp270096-tbl-0001" ref-type="table">1</xref>. A phosphodiester 12&#8208;mer with a full PO backbone (Compound 1) was used as a positive control, a 16&#8208;mer phosphorothioate LNA&#8208;DNA&#8208;LNA gapmer against MALAT1 (Compound 2) as a negative control, a 16&#8208;mer phosphodiester LNA&#8208;DNA&#8208;LNA gapmer against MALAT1 (Compound 4) to test the effect of LNAs on the nucleolytic activity of nucleases, and a 16&#8208;mer LNA&#8208;DNA&#8208;LNA gapmer with a mixed PS/PO backbone (PS&#8208;PO&#8208;PS&#8201;=&#8201;9&#8211;3&#8211;3 from 5&#8242; end, compound 5) as the target ASO. Compound 3 was an internal standard, while Compound 6 was target ASOs with sequences 1 and 2 and a PS/PO backbone. Details of the synthesis, purification, and analysis of these compounds are described in the Methods <xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S1</xref>. In the second part of the study, a total of 83 ASOs with two different sequences (Figure&#160;<xref rid="prp270096-fig-0001" ref-type="fig">1</xref>) and three different mixed PS/PO backbone patterns were synthesized and tested.</p><table-wrap position="float" id="prp270096-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Summary of oligonucleotides chosen for the studies.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Compound name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Purpose</th><th align="center" valign="bottom" rowspan="1" colspan="1">5&#8242; sequence 3&#8242;</th><th align="center" valign="bottom" rowspan="1" colspan="1">Length</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">12&#8208;mer</td><td align="center" valign="top" rowspan="1" colspan="1">Positive control</td><td align="center" valign="top" rowspan="1" colspan="1">AoGoCoToAoGoCoToAoGoCoT</td><td align="center" valign="top" rowspan="1" colspan="1">12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MALAT1&#8208;Full PS</td><td align="center" valign="top" rowspan="1" colspan="1">Negative control</td><td align="center" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">G</underline>
<sup>
<underline underline-style="single">Me</underline>
</sup>
<underline underline-style="single">CA</underline>TT<sup>Me</sup>CTAATA<sup>Me</sup>C<underline underline-style="single">AG</underline>
<sup>
<underline underline-style="single">Me</underline>
</sup>
<underline underline-style="single">C</underline>
</td><td align="center" valign="top" rowspan="1" colspan="1">16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MALAT1&#8208;Full P<sup>34</sup>S</td><td align="center" valign="top" rowspan="1" colspan="1">Internal standard</td><td align="center" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">G</underline>
<sup>
<underline underline-style="single">Me</underline>
</sup>
<underline underline-style="single">CA</underline>TT<sup>Me</sup>CTAATA<sup>Me</sup>C<underline underline-style="single">AG</underline>
<sup>
<underline underline-style="single">Me</underline>
</sup>
<underline underline-style="single">C</underline>
</td><td align="center" valign="top" rowspan="1" colspan="1">16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MALAT1&#8208;Full PO</td><td align="center" valign="top" rowspan="1" colspan="1">Impact of LNA on stability</td><td align="center" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">Go</underline>
<sup>
<underline underline-style="single">Me</underline>
</sup>
<underline underline-style="single">CoA</underline>oToTo<sup>Me</sup>CoToAoAoToAoGo<sup>Me</sup>Co<underline underline-style="single">AoGo</underline>
<sup>
<underline underline-style="single">Me</underline>
</sup>
<underline underline-style="single">C</underline>
</td><td align="center" valign="top" rowspan="1" colspan="1">16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sequence 1 (9&#8211;3&#8211;3)</td><td align="center" valign="top" rowspan="1" colspan="1">Target (PS/PO backbone)</td><td align="center" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">GTT</underline>TGGTATTo<sup>Me</sup>CoToT<underline underline-style="single">TAG</underline>
</td><td align="center" valign="top" rowspan="1" colspan="1">16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sequence 1<xref rid="prp270096-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" rowspan="2" valign="top" colspan="1">Target (PS/PO backbone)</td><td align="center" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">GTT</underline>TGGTATT<sup>Me</sup>CTT<underline underline-style="single">TAG</underline>
</td><td align="center" valign="top" rowspan="1" colspan="1">16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sequence 2<xref rid="prp270096-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">GAT</underline>TATTTA<sup>Me</sup>CT<sup>Me</sup>CA<underline underline-style="single">GGA</underline>
</td><td align="center" valign="top" rowspan="1" colspan="1">16</td></tr></tbody></table><table-wrap-foot id="prp270096-ntgp-0002"><fn id="prp270096-note-0002"><p>
<italic toggle="yes">Note:</italic> PO links are labeled as &#8220;o,&#8221; when not specified are PS modifications; lightface type, DNA; underline type, locked nucleic acid (LNA); <sup>Me</sup>C, 5&#8208;methylcytidine.</p></fn><fn id="prp270096-note-0003"><label>
<sup>a</sup>
</label><p>Descriptions of a mixed PS/PO backbone and PO walk are shown in Figure&#160;<xref rid="prp270096-fig-0001" ref-type="fig">1</xref>.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="prp270096-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Three backbone patterns of gapmer compounds with sequential replacement of PS backbone by one to three PO internucleotide linkages from 3&#8242; to 5&#8242; terminal (1 PO, 2 PO and 3 PO walk). Definitions: PS linker (red), PO linker (green in black box), DNA (light gray), LNA (blue). Numerical labelling of ASOs indicates the number of PS (red) and PO (green) modifications.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PRP2-13-e70096-g006.jpg"/></fig></sec><sec id="prp270096-sec-0005"><label>2.3</label><title>Preparation of Mouse Liver Homogenate</title><p>Mouse livers were perfused to remove blood and snap frozen until use. Frozen tissue was thawed on ice, cut with surgical scissors into small pieces, and placed in a round&#8208;bottom tube. Cold homogenization buffer (100&#8201;mM TRIS&#8211;HCl, 1&#8201;mM MgCl<sub>2</sub>, pH&#8201;7.5 adjusted with 10&#8201;M HCl) was added at a ratio of 1&#8201;g tissue/3&#8201;mL buffer (4 folds dilution). Tissue homogenization was performed on ice using a Polytron PT 1200 homogenizer (Kinematica AG, Luzern, Switzerland) for several cycles (cycle: 4&#8201;s on/4&#8201;s off) to achieve a well&#8208;homogenized material. The homogenate was collected in a 50&#8208;mL Falcon tube on ice and centrifuged at 1000&#215;<italic toggle="yes">g</italic> at +4&#176;C for 20&#8201;min (Rotina 38R, Hettich Labinstrument AB, Sigtuna, Sweden). The supernatant was collected in a Falcon tube, mixed, and aliquoted into 2&#8208;mL Eppendorf tubes. The tubes were snap frozen in a mixture of 99.5% ethanol and dry ice and subsequently stored at &#8722;80&#176;C. Prior to use, the homogenate was diluted with a cold homogenization buffer to obtain a final sixfold final dilution.</p></sec><sec id="prp270096-sec-0006"><label>2.4</label><title>Sample Preparation for Nuclease Saturation Experiment</title><p>DNA LoBind tubes were used to prepare solutions and samples for incubation. Standard solutions of ASOs were made in nuclease&#8208;free water with a concentration range of 100, 200, 300, 400, and 500&#8201;&#956;M. Mouse serum (Envigo, Indianapolis, IN, USA) was prepared by a 1:1 dilution with nuclease&#8208;free water. 50% mouse serum (68&#8201;&#956;L) was spiked with 2&#8201;&#956;L stock solution of ASOs, yielding incubation concentrations of 2.9, 5.7, 8.6, 11.4, and 14.3&#8201;&#956;M, respectively. The resultant mixtures were incubated in a water bath for 3 and 6&#8201;h at 37&#176;C. Following incubation, samples were quickly frozen in dry ice and stored at &#8722;20&#176;C. The nucleolytic reaction was stopped enzymatically with a quench solution (Tissue &amp; Cell Lysis Solution and Proteinase K) prepared according to the protocol published earlier [<xref rid="prp270096-bib-0022" ref-type="bibr">22</xref>]. Seventy microliters of stop solution were added to the frozen samples, and the quenched mixture was incubated at 60&#176;C for 1&#8201;h in a water bath, then centrifuged at 2330&#215;<italic toggle="yes">g</italic> at +4&#176;C for 15&#8201;min (Rotanta 460R, Hettich Labinstrument AB, Sigtuna, Sweden). Eighty microliters of supernatant were analyzed by HPLC&#8208;UV (Methods <xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="prp270096-sec-0007"><label>2.5</label><title>Sample Incubations for Stability Studies</title><sec id="prp270096-sec-0008"><label>2.5.1</label><title>Incubation With PDEI</title><p>In vitro stability of synthesized oligonucleotides was studied in PDEI from <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Crotalus adamanteus</italic>
</styled-content> (batches: SLCN1579, SLCP1594, vial of &#8805;&#8201;100&#8201;units, 95% purity, Merck Life Science, Solna, Sweden). The PDEI enzyme was dissolved in 1&#8201;mL nuclease&#8208;free water and aliquots (100&#8201;U/mL) were stored at &#8722;20&#176;C until use. The oligonucleotide working solutions were prepared in NaOAc buffer (50&#8201;mM NaOAc, 10&#8201;mM MgCl<sub>2</sub>, pH&#8201;=&#8201;7.4). All sample incubations were conducted in 96&#8208;well plates. For 20&#8208;h incubation, unused sample wells were filled with MilliQ water to maintain the surrounding humidity and temperature of the test sample wells, and the plates were prewarmed at 37&#176;C for 2&#8201;h. The reaction was initiated by adding oligonucleotide working solutions to aliquoted PDEI. The final incubation mixture contained 5&#8201;&#956;M ASO compound and 86&#8201;mU PDEI in 120&#8201;&#956;L incubation media. Prior to incubation, plates were centrifuged for a few seconds at 150&#215;<italic toggle="yes">g</italic> at +4&#176;C. Plates prepared for 0&#8208;h incubation were immediately stored at &#8722;80&#176;C, while plates to be incubated for 20&#8201;h were sealed with PTFE/Silicone Cap Mat (Waters Sverige AB, Solna, Sweden) and incubated at 37&#176;C in an in&#8208;house&#8208;made shaking incubator. After incubation, sample plates were sealed with Corning 96&#8208;well Microplate Aluminum Sealing Tapes (Thermo Fisher, Stockholm, Sweden) and immediately stored at &#8722;80&#176;C until sample preparation using solid&#8208;phase extraction (SPE) and UPLC&#8211;MS analysis.</p></sec><sec id="prp270096-sec-0009"><label>2.5.2</label><title>Incubation With Mouse Serum and Mouse Liver Homogenate</title><p>The oligonucleotide stock solutions were prepared in nuclease&#8208;free water. Mouse serum (Merck Life Science, Solna, Sweden) or mouse liver homogenate, both 119&#8201;&#956;L in volume, were added to previously aliquoted ASOs (0.6&#8201;nmol, 1&#8201;&#956;L of 600&#8201;&#956;M stock solution) in DNA LoBind 96&#8208;well plates. The final concentration of analytes was 5&#8201;&#956;M in 120&#8201;&#956;L. The sample preparation procedure was the same as for incubation with PDEI (vide supra). Plates for 20&#8208;h incubation were covered with Breathe&#8208;Easy sealing membrane (Merck Life Science, Solna, Sweden) prior to placement in the in&#8208;house&#8208;made shaking incubator. All samples were stored at &#8722;80&#176;C until subjected to SPE sample preparation and UPLC&#8211;MS analysis.</p></sec></sec><sec id="prp270096-sec-0010"><label>2.6</label><title>
<styled-content style="fixed-case" toggle="no">SPE</styled-content> Protocol</title><p>Frozen previously incubated samples were thawed at room temperature, centrifuged for 1&#8201;min at 240&#215;<italic toggle="yes">g</italic> at +4&#176;C, and kept on ice. An aliquot of 80&#8201;&#956;L sample was added into 90&#8201;&#956;L of quench solution premixed with 10&#8201;&#956;L of 4&#8201;&#956;M internal standard (MALAT1&#8208;Full P<sup>34</sup>S) previously aliquoted to each well in a DNA LoBind 96&#8208;well plate. The final concentration of the internal standard after SPE and reconstitution in 80&#8201;&#956;L nuclease&#8208;free water was 0.5&#8201;&#956;M. The quench solution (6&#8201;M guanidine hydrochloride, 1% Tergitol, 10&#8201;mM TCEP, 8&#8201;mM <sc>l</sc>&#8208;cysteine) was always prepared fresh on the day of use and stored at +4&#176;C. The plate was shaken on an Eppendorf MixMate (VWR, Stockholm, Sweden) at 800&#8201;rpm for 15&#8201;min and then centrifuged at 245&#215;<italic toggle="yes">g</italic> for 1&#8201;min. Afterwards, the plate was transferred to an automated sample preparation workstation (Extrahera LV&#8208;200, Biotage, Uppsala, Sweden) for SPE sample extraction. The SPE buffers were prepared as follows: equilibration buffer: 50&#8201;mM NH<sub>4</sub>OAc (pH&#8201;=&#8201;5.5); wash buffer (1): 50&#8201;mM NH<sub>4</sub>OAc (pH&#8201;=&#8201;5.5) was mixed with ACN (50:50 [v:v]&#8201;=&#8201;water:ACN, final concentration of NH<sub>4</sub>OAc was 25&#8201;mM); wash buffer (2): 3&#8201;M guanidine hydrochloride, 1% Tergitol; elution buffer: 200&#8201;mM NH<sub>4</sub>HCO<sub>3</sub> (pH&#8201;=&#8201;9.5) was mixed with ACN and THF (50:40:10 [v:v:v]&#8201;=&#8201;water:ACN:THF, final concentration of NH<sub>4</sub>HCO<sub>3</sub> was 100&#8201;mM). The pH was adjusted using a high concentration of acetic acid for the preparation of 50&#8201;mM NH<sub>4</sub>OAc and ammonium hydroxide for the preparation of 200&#8201;mM NH<sub>4</sub>HCO<sub>3</sub>.</p><sec id="prp270096-sec-0011"><label>2.6.1</label><title>PDEI and Mouse Serum SPE Protocol</title><p>Biotage Evolute Oligo 1, 30&#8201;mg plates was used to run SPE on samples incubated with PDEI and mouse serum. SPE plates were conditioned once with 500&#8201;&#956;L methanol followed by equilibration with 750&#8201;&#956;L equilibration buffer one time, after which the plate was left to dry for 5&#8201;s. The samples in the DNA LoBind 96&#8208;well plate were pretreated by adding 180&#8201;&#956;L equilibration buffer to each well and 335&#8201;&#956;L of the mixture was loaded onto the conditioned and equilibrated SPE plate followed by five times premixing (applied pressure: 0.1&#8201;bar, 160&#8201;s; 0.2&#8201;bar, 160&#8201;s; 1&#8201;bar, 60&#8201;s). The SPE plate was washed three times with 500&#8201;&#956;L wash buffer (1) (applied pressure: 0.8&#8201;bar, 45&#8201;s; 1&#8201;bar, 45&#8201;s). The plate was left to dry for 30&#8201;s prior to the elution step. The samples were eluted two times by adding 250&#8201;&#956;L elution buffer (applied pressure: 0&#8201;bar, 120&#8201;s; 0.4&#8201;bar, 120&#8201;s) and collected in the DNA LoBind 96&#8208;well plate.</p></sec><sec id="prp270096-sec-0012"><label>2.6.2</label><title>Mouse Liver Homogenate <styled-content style="fixed-case" toggle="no">SPE</styled-content> Protocol</title><p>SPE was done on Clarity OTX 25&#8201;mg/well plates. The protocol was the same as previously described (vide supra) with the following modifications: SPE washing phase was done in two steps. First, samples were washed once with 500&#8201;&#956;L wash buffer (2), and afterwards three times with 500&#8201;&#956;L wash buffer (1). During both steps, the applied pressure was 0.8&#8201;bar, 45&#8201;s; 1&#8201;bar, 45&#8201;s; 2&#8201;bar, 45&#8201;s. The plate was left to dry for 30&#8201;s prior to the elution step. The samples were eluted two times with 250&#8201;&#956;L elution buffer (applied pressure: 0&#8201;bar, 120&#8201;s; 0.4&#8201;bar, 120&#8201;s; 2.5&#8201;bar, 120&#8201;s) and collected in a DNA LoBind 96&#8208;well plate.</p><p>After SPE, all extracted sample plates were dried overnight under nitrogen flow at room temperature (Techne 96&#8208;Well Sample Concentrator [Minneapolis, MN, USA]). Sealed plates were stored at &#8722;20&#176;C or directly reconstituted forUPLC&#8208;MS analysis.</p></sec></sec><sec id="prp270096-sec-0013"><label>2.7</label><title>UPLC&#8208;QToF MS Analysis</title><p>Prior to LC&#8208;MS analysis, all SPE samples were reconstituted in 80&#8201;&#956;L nuclease&#8208;free water, followed by shaking at 800&#8201;rpm for 20&#8201;min (Eppendorf MixMate, VWR, Stockholm, Sweden) and centrifuged at 2700&#215;<italic toggle="yes">g</italic> for 10&#8201;min at +4&#176;C. LC&#8208;MS analysis was carried out using a 1290 Infinity UPLC system (Agilent Technologies, Santa Clara, CA, USA) comprised of a binary pump, a thermostatically controlled column compartment, and an autosampler coupled to a HP Agilent 1100 HPLC G1315A Diode Array Detector (DAD) and 6560 Ion Mobility LC/QToF mass analyzer (Agilent Technologies, Santa Clara, CA, USA). Chromatographic separation was achieved using a UPLC Acquity Premier Oligonucleotide BEH C18 column (130&#8201;&#197;, 1.7&#8201;&#956;m, 2.1&#8201;mm&#8201;&#215;&#8201;100&#8201;mm; Waters [Solna, Sweden]) heated at 60&#176;C. Mobile phase (A) was an aqueous solution of 200&#8201;mM HFIP and 7.5&#8201;mM TEA; mobile phase (B) was 100% methanol. There was no pH adjustment done on mobile phase (A). Injection volume was 5&#8201;&#956;L, and the flow rate was 0.3&#8201;mL/min. Chromatographic separation was done under the following gradient (min&#8211;%B): 0&#8211;5; 1&#8211;5; 4&#8211;15; 10&#8211;30; 10.5&#8211;80; 12.5&#8211;80; 13&#8211;5. The total run time was 14&#8201;min.</p><p>UV detection was performed using DAD (260&#8201;nm, spectral bandwidth 4&#8201;nm), and the mass spectrometer was configured with a Dual Agilent Jet Stream Electrospray Ionization (Dual AJS ESI) source. The ion source operated with the following parameters: gas temperature (300&#176;C), drying gas (8&#8201;L/min), nebulizer gas pressure (35&#8201;psi), sheath gas temperature (350&#176;C), sheath gas flow (11&#8201;L/min), capillary voltage (3.5&#8201;kV), and nozzle voltage (1&#8201;kV). The mass spectrometer operated in negative ion mode (<italic toggle="yes">m/z</italic> scan range: 600&#8211;3000) with 28,000 mass resolving power at <italic toggle="yes">m/z</italic> 1900. Instrument control and data acquisition were done using MassHunter Workstation LC/MS Data Acquisition software (version B.09.00, build 9.0.9044.1 SP1, Agilent technologies Inc. 2018). Data analysis was performed using MassHunter Workstation Qualitative Analysis software (version 10.0, build 10.0.10305.0, Agilent technologies Inc. 2006&#8211;2018). The envelope peaks of &#8722;3 charged ions of interest were integrated as single <italic toggle="yes">m/z</italic> expansion for chromatogram (symmetric, &#177;1&#8201;<italic toggle="yes">m/z</italic>). For data processing, selected samples were also analyzed by UPLC&#8208;orbitrap MS (Thermo Fisher Scientific). Details of UPLC separation and orbitrap MS conditions are shown in Methods <xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="prp270096-sec-0014"><label>2.8</label><title>Data Analysis for Metabolite Profiling and Identification</title><p>Representative incubated in&#160;vitro samples analyzed by UPLC&#8208;QToF MS or Orbitrap MS were processed for metabolite identification and profiling using Mass&#8208;MetaSite V4.6, Macro Molecules mode, in Oniro WebMetaBase platform (Mass Analytica, Spain) or BioPharma Finder V5.1 oligonucleotide analysis module (Thermo Fisher Scientific). Expected degradation reactions such as hydrolysis of the internucleotide bond and deamination were considered.</p></sec></sec><sec sec-type="results" id="prp270096-sec-0015"><label>3</label><title>Results</title><sec id="prp270096-sec-0016"><label>3.1</label><title>Stability Assessments of Oligonucleotides Toward <styled-content style="fixed-case" toggle="no">PDEI</styled-content> and Mouse Serum</title><p>Initial stability investigations were performed with snake venom PDEI, a 3&#8242;&#8201;&#8594;&#8201;5&#8242; exonuclease [<xref rid="prp270096-bib-0023" ref-type="bibr">23</xref>, <xref rid="prp270096-bib-0024" ref-type="bibr">24</xref>, <xref rid="prp270096-bib-0025" ref-type="bibr">25</xref>, <xref rid="prp270096-bib-0026" ref-type="bibr">26</xref>], to establish conditions that fully degraded an unmodified PO&#8208;ASO (&#8220;12&#8208;mer&#8221;) (Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S1</xref>). Then, stability assessment of the ASOs was performed with 86&#8201;mU of PDEI for 0, 1, 3, and 20&#8201;h, and analyzed by gel electrophoresis (Methods <xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S1</xref>).</p><p>As shown in Figure&#160;<xref rid="prp270096-fig-0002" ref-type="fig">2</xref>, the assay conditions allow for a clear differentiation between the stable MALAT1&#8208;Full PS gapmer and the hydrolysable MALAT1&#8208;Full PO with LNA in the wings (Table&#160;<xref rid="prp270096-tbl-0001" ref-type="table">1</xref>, no. 4). We further tested a mixed PS/PO backbone ASO (&#8220;sequence1 [9&#8211;3&#8211;3]&#8221;; Compound 5, Table&#160;<xref rid="prp270096-tbl-0001" ref-type="table">1</xref>). Interestingly, this ASO showed a degradation time profile comparable to the full&#8208;PO (Figure&#160;<xref rid="prp270096-fig-0002" ref-type="fig">2</xref>, lane 4 vs. lane 3). The LNA modification at the wings increased stability for 1 to 3&#8201;h (12&#8208;mer vs. MALAT1&#8208;Full PO and Sequence 1 [9&#8211;3&#8211;3]).</p><fig position="float" fig-type="FIGURE" id="prp270096-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Nuclease assay for stability assessment of selected compounds (Table&#160;<xref rid="prp270096-tbl-0001" ref-type="table">1</xref>) incubated with phosphodiesterase I (3&#8242;&#8201;&#8594;&#8201;5&#8242;) for 0, 1, 3, and 20&#8201;h. Positive control: 12&#8208;mer; negative control: MALAT1&#8208;Full PS; the effect of LNAs on stability: MALAT1&#8208;Full PO; mixed PO/PS backbone: Compound with sequence 1 and 3 PO walk from 5&#8242;&#8594;&#8201;3&#8242; end in order 9 PS 3 PO 3 PS: Sequence 1 (9&#8211;3&#8208;3). (A) a summary of gel images, (B) band analysis showing remaining percentage of selected compounds after incubation with PDEI. Data represent mean and SEM from <italic toggle="yes">n</italic>&#8201;=&#8201;2 replicates, 4 data points.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PRP2-13-e70096-g001.jpg"/></fig><p>Based on these findings, we explored the impact of varying PO content and positions in the backbone of an ASO gapmer. A total of 83 ASOs with two different sequences (Figure&#160;<xref rid="prp270096-fig-0001" ref-type="fig">1</xref>), and three different mixed PS/PO backbone patterns were synthesized and tested. All ASOs (both sequences and all three PO walks) were incubated under the same conditions: 0.6&#8201;nmol ASO with 86&#8201;mU of PDEI for 20&#8201;h at 37&#176;C. Samples were prepared with solid&#8208;phase extraction (SPE, details in Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S2</xref>), achieving a mean extraction recovery of 68%&#8201;&#177;&#8201;6% for all three reference ASOs (Methods <xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S1</xref> and Table&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S1</xref>). Following SPE, the samples were analyzed using UPLC&#8211;high&#8208;resolution MS. A set of typical stability assessment chromatograms of one ASO is shown in Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S3</xref>.</p><p>A comprehensive overview of the metabolic stability of all ASOs incubated with PDEI is presented in Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3</xref> and Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S4</xref>, revealing several noteworthy observations. It was observed that all ASOs with PO linkage(s) at the very 3&#8242; end (14&#8211;1; 13&#8211;2; 12&#8211;3, labeled as 0 in Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3</xref>) are completely metabolized over a 20&#8208;h incubation period. This indicates that LNAs do not offer protection against PDEI when one or more PO modifications are located closest to the 3&#8242; end. Conversely, if one or two PS modifications are positioned at the 3&#8242; end of an ASO backbone, LNA chemistry provides protection.</p><fig position="float" fig-type="FIGURE" id="prp270096-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Comparison of stability for 5&#8201;&#956;M ASOs with varied PO and PS composition and explored for two different oligonucleotide sequences incubated for 20&#8201;h with 86&#8201;mU PDEI (light gray) or 100% mouse serum (dark gray). Top panel: 1 PO walk; middle panel: 2 PO walk; bottom panel: 3 PO walk. (A) sequence 1, (B) sequence 2. Data represent mean and SEM from <italic toggle="yes">n</italic>&#8201;=&#8201;3 replicates.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="PRP2-13-e70096-g002.jpg"/></fig><p>ASO stability was further tested in mouse serum, known for its high 3&#8242;&#8208;exonuclease content [<xref rid="prp270096-bib-0027" ref-type="bibr">27</xref>]. Both series of analytes (sequence 1 and 2 with three different PO walks, respectively) were incubated in 100% serum, mirroring the approach with PDEI (Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3</xref> and Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S5</xref>). The general trend of higher PS content in an ASO leading to higher stability was confirmed in line with previous observations [<xref rid="prp270096-bib-0020" ref-type="bibr">20</xref>, <xref rid="prp270096-bib-0028" ref-type="bibr">28</xref>]. However, our findings also indicate that nucleolytic stability is contingent upon the sequence, with sequence 1 exhibiting greater stability compared to sequence 2 (Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3</xref>). Similar to the findings with PDEI, LNAs did not provide protection to ASOs with 1, 2, or 3 PO linkages at the 3&#8242; end as they appeared to be completely metabolized after 20&#8201;h of incubation. Conversely, ASOs with one or two PS modifications at the 3&#8242; end (in the LNA wing) showed higher stability, and this stability did not seem to be sequence&#8208;dependent as observed with PDEI.</p><p>We compared nucleolytic stability of ASOs exposed to PDEI and mouse serum to assess whether the nucleolytic potential of 86&#8201;mU PDEI matches 100% mouse serum. Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3A</xref> shows the comparison in stability between two nucleolytic matrices, PDEI and mouse serum, for sequence 1. Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3B</xref> displays stability results of sequence 2. It is observed in Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3B</xref> that metabolic degradation is very similar between PDEI and mouse serum, especially for ASOs with 1 PO modification in the backbone (top graph). The stability of ASOs with the 2 PO and 3 PO walk in the 3&#8242; LNA wing for sequence 2 (Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3B</xref>, middle and bottom graphs), appears higher in PDEI than in mouse serum. This is contrasting to the observations for sequence 1 (Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3A</xref>, middle and bottom graphs), which is observed to be more stable in mouse serum (discussed later).</p><p>As expected, when comparing the stability of ASOs with different PO content, we observed that higher PO content in a backbone decreases stability toward both nucleolytic matrices in both sequences (Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3</xref>). Additionally, we found that having nine consecutive PS modifications at the 3&#8242; end does not block exonuclease activity. However, we noticed increased stability in some compounds with PO linkages before Position 9. Specifically, ASOs with a PS to PO swap after 5&#8208;methylcytidine (<sup>Me</sup>C) from the 3&#8242; end showed increased stability (sequence 1 [9&#8211;1&#8211;5] and sequence 2 [10&#8211;1&#8211;4 and 8&#8211;1&#8211;6]), while a PS to PO swap before <sup>Me</sup>C from the 3&#8242; terminal resulted in decreased stability (Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3</xref> top panel and Figure&#160;<xref rid="prp270096-fig-0004" ref-type="fig">4</xref>). Furthermore, enhanced stability was observed when the PS to PO swap was located between thymidine and adenosine nucleosides in the direction 5&#8242; T&#8211;A 3&#8242; (sequence 1 [6&#8211;1&#8208;8] and sequence 2 [7&#8211;1&#8211;7]), but not between 5&#8242; A&#8211;T 3&#8242; or 5&#8242; T&#8211;T 3&#8242; (Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3</xref> top panel and Figure&#160;<xref rid="prp270096-fig-0004" ref-type="fig">4</xref>). We observed a similar trend for sequence 2 ASOs with 2 PO and 3 PO walks, particularly noting increased stability for specific patterns; it is evident that sequence&#8208;dependent stability is more readily observed for the ASOs with 1 PO walk than for 2 PO and 3 PO walks.</p><fig position="float" fig-type="FIGURE" id="prp270096-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Structural schematic of selected ASO molecules with 1 PO walk reflecting how the position of PO modification in a backbone towards 5&#8208;methylcytidine (<sup>Me</sup>C), thymidine (T) and adenosine (A) nucleosides impacts the stability (based on data from Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3</xref>, top panel).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="PRP2-13-e70096-g007.jpg"/></fig></sec><sec id="prp270096-sec-0017"><label>3.2</label><title>Stability Study of <styled-content style="fixed-case" toggle="no">ASOs</styled-content> in Mouse Liver Homogenate. Comparison of Metabolic Profiles in Biological Matrices</title><p>After observing the intriguing stability increase associated with sequence&#8208;dependent PS to PO swaps following incubations with mouse serum and PDEI, we aimed to explore whether these patterns could be observed in a more complex biological matrix, such as mouse liver homogenate.</p><p>Figure&#160;<xref rid="prp270096-fig-0005" ref-type="fig">5</xref> provides a direct comparison of ASO stability in mouse serum and mouse liver homogenate for ASOs with 1 PO walk for both sequences. The inherent stability of the mixed PS/PO backbone patterns in both matrices shows a strong correlation, particularly for sequence 2 (Figure&#160;<xref rid="prp270096-fig-0005" ref-type="fig">5B</xref>). However, under these incubation conditions, ASOs were generally more stable in liver homogenate than in serum (Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S6</xref>).</p><fig position="float" fig-type="FIGURE" id="prp270096-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Correlation of metabolic stability for 5&#8201;&#956;M ASOs with 1 PO link in the backbone and explored for sequence 1 (A) and sequence 2 (B) incubated for 20&#8201;h in mouse serum and mouse liver homogenate. There is a strong correlation of stability for ASOs with both sequences in mouse serum and mouse liver homogenate (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001 for A and B).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="PRP2-13-e70096-g005.jpg"/></fig><p>In addition to the stability studies, we conducted metabolite identification analysis using HRMS. Several compounds showing increased stability (summarized in Figure&#160;<xref rid="prp270096-fig-0004" ref-type="fig">4</xref>) and sequence 2 (5&#8211;1&#8211;9) showing decreased stability were selected for analysis. Similar metabolite profiles were obtained using software data processing, Mass&#8208;MetaSite or BioPharma Finder. Further structure identification was confirmed by BioPharma Finder Oligonucleotide sequence analysis based on MS/MS fragment analysis (Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S7</xref>). Table&#160;<xref rid="prp270096-tbl-0002" ref-type="table">2</xref> represents the metabolic profile for sequence 2 (10&#8211;1&#8211;4), and metabolic identification of other ASOs is summarized in Table&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S2</xref>. Our analysis revealed that mouse serum, mouse liver homogenate, and PDEI showed a similar hydrolytic pattern, with endonuclease cleavage predominantly at the PO linkage, followed by 3&#8242;&#8208;exonuclease degradation towards the 5&#8242; end, and the direct deletion of one nucleotide from the 3&#8242; end (3&#8242; N&#8208;1) of the full&#8208;length ASO.</p><table-wrap position="float" id="prp270096-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>An example of metabolite profiling for compound Sequence 2 (10&#8211;1&#8211;4) incubated in mouse serum, mouse liver homogenate and PDEI for 20&#8201;h at 37&#176;C.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">5&#8242; compound 3&#8242;</th><th align="center" colspan="3" valign="bottom" rowspan="1">Relative peak area (%)<xref rid="prp270096-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Mouse serum</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mouse liver homogenate</th><th align="center" valign="bottom" rowspan="1" colspan="1">PDEI</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="4" valign="top" rowspan="1">10&#8211;1&#8211;4 (Sequence 2)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">GAT</underline>TATTTA<sup>Me</sup>CTo<sup>Me</sup>CA<underline underline-style="single">GGA</underline>
</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">52</td><td align="center" valign="top" rowspan="1" colspan="1">70</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">GAT</underline>TATTTA<sup>Me</sup>CTo<sup>Me</sup>CA<underline underline-style="single">GG</underline>
</td><td align="center" valign="top" rowspan="1" colspan="1">13<xref rid="prp270096-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">GAT</underline>TATTTA<sup>Me</sup>CT</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">GAT</underline>TATTTA<sup>Me</sup>C</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">GAT</underline>TATTTA</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">GAT</underline>TATTT</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">
<underline underline-style="single">GAT</underline>TATT</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">
<sup>Me</sup>CA<underline underline-style="single">GGA</underline>
</td><td align="center" valign="top" rowspan="1" colspan="1">11<xref rid="prp270096-note-0007" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3<xref rid="prp270096-note-0007" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">13</td></tr></tbody></table><table-wrap-foot id="prp270096-ntgp-0003"><fn id="prp270096-note-0004"><p>
<italic toggle="yes">Note:</italic> PO links are labeled as &#8220;o,&#8221; when not specified are PS modifications; lightface type, DNA; underline type, locked nucleic acid (LNA); <sup>Me</sup>C, 5&#8208;methylcytidine. Relative abundances of parent or metabolite were calculated as a ratio of MS peak areas of each analyte to the total area of identified metabolite and parent. The differences in MS responses and SPE recoveries of parent and metabolites were not taken into account for quantification.</p></fn><fn id="prp270096-note-0005"><label>
<sup>a</sup>
</label><p>Values reported by Mass&#8208;MetaSite.</p></fn><fn id="prp270096-note-0006"><label>
<sup>b</sup>
</label><p>Present in 0&#8201;h sample.</p></fn><fn id="prp270096-note-0007"><label>
<sup>c</sup>
</label><p>With/without 5&#8242; terminal phosphate.</p></fn></table-wrap-foot></table-wrap><p>In order to develop an in&#160;vitro screening assay capable of capturing the nucleolytic potency of biological matrices, we screened various known nucleases alongside PDEI to assess their suitability. The properties of selected nucleases are described in Table&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S3</xref>. A 12&#8208;mer at a concentration of 4.8&#8201;&#956;M (0.6&#8201;nmol) was incubated with six different nucleases for 20&#8201;h at 37&#176;C (Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S8</xref>). Four nucleases, exonuclease T (ExoT), exonuclease VII (ExoVII), nuclease P1 (NucP1), and T5 exonuclease (T5Exo) completely degraded the 12&#8208;mer. We then tested the stability of MALAT1&#8208;Full PO (Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S9</xref>) and MALAT1&#8208;Full PS (Figure&#160;<xref rid="prp270096-fig-0006" ref-type="fig">6</xref>) after incubation for 20&#8201;h at 37&#176;C with the selected nucleases. Under these incubation conditions, only ExoVII and NucP1 completely degraded MALAT1&#8208;Full PO (0.6&#8201;nmol), while MALAT1&#8208;Full PS (0.6&#8201;nmol) was degraded by the endonuclease NucP1. Interestingly, although ExoVII, a bidirectional nuclease, should not be inhibited by presence of a full PS backbone, we did not observe hydrolysis of MALAT1&#8208;Full PS after incubation with 10&#8201;U of this enzyme (Figure&#160;<xref rid="prp270096-fig-0006" ref-type="fig">6</xref>).</p><fig position="float" fig-type="FIGURE" id="prp270096-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Titration of MALAT1&#8208;Full PS (4.8&#8201;&#956;M) with selected nucleases. The enzymatic activity of nucleases was 10&#8201;U, except for Nuclease P1, which was 5&#8201;U. Incubation was done for 0 and 20&#8201;h. (A) a summary of gel images, (B) band analysis showing the remaining percentage of MALAT1&#8208;Full PS after incubation with selected enzymes. Data represent the mean from <italic toggle="yes">n</italic>&#8201;=&#8201;1 replicates, 2 data points.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="PRP2-13-e70096-g003.jpg"/></fig></sec></sec><sec sec-type="discussion" id="prp270096-sec-0018"><label>4</label><title>Discussion</title><p>This work represents a comprehensive series of in&#160;vitro ASO stability assessments in different matrices, purified snake venom PDEI, mouse serum, and mouse liver homogenate. The examination of 83 ASOs with two sequences and various PO/PS content revealed structure&#8208;dependent stability patterns. The data obtained from the nucleolytic sensitivity observed with 3&#8242;&#8211;exonuclease PDEI and mouse serum demonstrate a dependence on both PO content and sequence composition. It is evident that (i) a lower PO content in the PS&#8208;modified oligonucleotide backbone provides higher stability, in keeping with established knowledge; and (ii) novel structural insights show how the backbone's base sequence has a larger impact on stability with increased PS content. With regards to (i), it has consistently been shown how the stability of mixed PS/PO ASOs considerably drops when exchanging three or more PS links with PO modifications [<xref rid="prp270096-bib-0020" ref-type="bibr">20</xref>, <xref rid="prp270096-bib-0028" ref-type="bibr">28</xref>]. However, this effect was possible to mitigate by introducing 2&#8242;&#8208;sugar modifications such as BNAs [<xref rid="prp270096-bib-0020" ref-type="bibr">20</xref>, <xref rid="prp270096-bib-0025" ref-type="bibr">25</xref>].</p><p>In contrast to previous reports suggesting that LNA&#8208;bases in the wings of PO&#8208;oligonucleotide gapmers provide protection against nuclease&#8208;hydrolysis [<xref rid="prp270096-bib-0029" ref-type="bibr">29</xref>], this study observed that gapmer PO MALAT1&#8208;LNA ASOs are degradable with 3&#8242;&#8208;exonucleases, both PDEI and mouse serum.</p><p>A notable pattern is that purine&#8208;base&#8208;rich oligonucleotides are generally more stable than pyrimidine&#8208;base&#8208;rich oligonucleotides [<xref rid="prp270096-bib-0030" ref-type="bibr">30</xref>]. By closer inspection of the composition of the last four nucleotides from the 3&#8242; end, sequence 1 contains 50% purines, while sequence 2 only carries purine nucleobases in this region (Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S10</xref>). It is observed that the ASOs from sequence 2 with the PO walk in the LNA flanking region at the 3&#8242; end are more stable compared to sequence 1 (Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3</xref> and Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S4</xref>), consistent with previously published data&#160;[<xref rid="prp270096-bib-0030" ref-type="bibr">30</xref>]. However, the mere relationship that sequence 2 with overall 50% purine content would be more stable than sequence 1 with 37.5% purine bases is not evident in this study, except when focusing on the LNA wings. The pyrimidine&#8208;base richer sequence 1 is even more stable than sequence 2 when exposed to mouse serum or mouse liver homogenate. However, it can be reasoned that the difference of six or eight purine bases in a 16&#8208;mer may be too small to yield a significant impact, and a more detailed understanding of the impact of base sequence on stability would aid rational ASO drug design.</p><p>Another systematically investigated chemical modification is cytosine methylation. Specifically, 5&#8208;methylcytosine (<sup>Me</sup>C) is a common c modification found in vertebrate and plant DNA, constituting 1%&#8211;5% of the total DNA. This modification can enhance RNA&#8211;DNA heteroduplex stability, mitigate the negative impact of full PS&#8208;ASOs on intrinsic immune response, regulate metabolism, and conciliate stress&#8208;induced cellular survival. In eukaryotes, gene expression activation is directly linked to cytosine methylation, while in prokaryotes, <sup>Me</sup>C plays a role in controlling gene expression as well as in the diminution of endonucleases [<xref rid="prp270096-bib-0031" ref-type="bibr">31</xref>, <xref rid="prp270096-bib-0032" ref-type="bibr">32</xref>, <xref rid="prp270096-bib-0033" ref-type="bibr">33</xref>, <xref rid="prp270096-bib-0034" ref-type="bibr">34</xref>, <xref rid="prp270096-bib-0035" ref-type="bibr">35</xref>].</p><p>In this study, we observed the impact of a <sup>Me</sup>C on the stability of ASOs, particularly for the 1 PO walk. We found that exchanging PS to PO link after <sup>Me</sup>C from the 3&#8242; end increases resistance toward nuclease hydrolysis, while the same exchange before <sup>Me</sup>C has no protective effect. This suggests that nuclease access to PO links for hydrolysis is hampered by the neighboring <sup>Me</sup>C, possibly due to the orientation of the methyl group introducing a steric block. Additionally, we observed another sequence&#8208;dependent phenomenon: increased stability of ASOs when PS was exchanged for PO between thymidine and adenosine nucleosides in the direction 5&#8242; T&#8211;A 3&#8242;. However, when the PS to PO exchange is located between 5&#8242; A&#8211;T 3&#8242; or 5&#8242; T&#8211;T 3&#8242;, no protective effect is observed.</p><p>One goal of this study was to explore the potential replacement of biological matrices such as mouse serum with alternative enzymatic systems possessing 3&#8242; exonuclease activity (Table&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S3</xref>). The use of nucleases, either in isolation or as a mixture, would reduce the need for animal&#8208;origin biological matrices in line with the principles of the 3Rs. Our findings demonstrated that PDEI shows similar hydrolysis potency as mouse serum towards ASOs with sequence 2 and 1 PO walk (Figure&#160;<xref rid="prp270096-fig-0003" ref-type="fig">3B</xref>, top graph), contrary to expectations due to the perception of PDEI as a pure 3&#8242; exonuclease. Previous reports suggested that exonuclease activity was completely blocked by five consecutive PS modifications [<xref rid="prp270096-bib-0036" ref-type="bibr">36</xref>]; however, our study found that PDEI degrades ASOs even with nine PS modifications from the 3&#8242; end, and good stability required 11 consecutive PS modifications (Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S4</xref>). This observation aligns with the additional endonucleolytic capability of PDEI also reported by others [<xref rid="prp270096-bib-0037" ref-type="bibr">37</xref>]. While Eder and his group reported that ASOs are specifically degraded by 3&#8242; exonucleases in serum [<xref rid="prp270096-bib-0027" ref-type="bibr">27</xref>], another group has shown that the endonuclease DNase1 is a major mouse serum nuclease that cleaves single&#8208;stranded DNA [<xref rid="prp270096-bib-0038" ref-type="bibr">38</xref>]. Our direct comparison of nuclease&#8208;mediated hydrolysis in PDEI and mouse serum shows highly similar stability patterns in all PO walks, supporting the fact that both, PDEI and mouse serum exhibit endonuclease activity (Table&#160;<xref rid="prp270096-tbl-0002" ref-type="table">2</xref> and Table&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><p>Building on the stability investigation for ASOs with both sequences and the 1 PO walk, we utilized a more complex nucleolytic matrix, mouse liver homogenate, and compared the data to that obtained with mouse serum. The biological matrices showed a strong correlation in stability, especially for sequence 2, with sequence 1 generally exhibiting higher stability in both matrices compared to sequence 2. ASOs displayed a trend of generally being more stable in mouse liver homogenate (Figure&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S6</xref>). This could be attributable to ASOs binding to liver proteins, reducing the free fraction available to nucleases. Alternatively, the proportion of nucleases in the total protein content of the homogenate may be smaller than in serum or in isolated enzyme PDEI. Comparing the biotransformation data from the three in&#160;vitro systems revealed similar metabolic profiles, with endonuclease activity occurring first, followed by 3&#8242;&#8211;exonuclease degradation (Table&#160;<xref rid="prp270096-tbl-0002" ref-type="table">2</xref> and Table&#160;<xref rid="prp270096-supitem-0001" ref-type="supplementary-material">S2</xref>). Previous work by Li et&#160;al. [<xref rid="prp270096-bib-0039" ref-type="bibr">39</xref>] has shown that in&#160;vivo metabolite profiles of a GalNAc<sub>3</sub>&#8208;conjugated full PS gapmer ASO in different animal species and human display a similar pattern, aligning with our in&#160;vitro findings.</p><p>As the mouse matrices as well as the PDEI incubations could replicate the in&#160;vivo observations [<xref rid="prp270096-bib-0039" ref-type="bibr">39</xref>] that ASO gapmer degradation begins with endonuclease&#8208;mediated cleavage, followed by 5&#8242;&#8208;and 3&#8242;&#8208;exonuclease&#8208;mediated hydrolysis, there is the opportunity that simple enzyme systems can be applied to generate in&#160;vivo metabolites. To explore the concept, the most stable reference compound in the dataset, the MALAT1&#8208;Full PS ASO, was exposed to other nucleases. With the high&#8208;activity endonuclease NucP1, a complete hydrolysis of the MALAT1&#8208;Full PS was achieved in&#160;vitro. Additionally, nuclease screening identified the potential of a bidirectional exonuclease, exonuclease VII, to hydrolyse MALAT1&#8208;Full PO. These findings can form the foundation for an in&#160;vitro nuclease capable of replicating additional nucleolytic activities and metabolite patterns observed in&#160;vivo. The availability of such an in&#160;vitro method to predict metabolic liabilities is fully aligned with the emerging regulatory expectations that in&#160;vitro methods shall be considered in the nonclinical safety assessment of oligonucleotides [<xref rid="prp270096-bib-0040" ref-type="bibr">40</xref>]. In a drug discovery setting, in&#160;vitro studies can guide the selection of the most stable ASO molecules prior to in&#160;vivo testing and replace animal serum and tissue homogenate incubations in compliance with the 3R perspective.</p><p>In conclusion, the assessment of ASO stability prior to in&#160;vivo ADME studies is an essential part of the design&#8211;make&#8211;test&#8211;analyze cycle. We have established a robust in&#160;vitro assay to determine the stability of newly synthesized ASOs with varying PS/PO content and sequence compositions.</p></sec><sec id="prp270096-sec-0022"><title>Author Contributions</title><p>
<italic toggle="yes">Participated in research design</italic>: Jelena Lovri&#263;, Jingjing Yan, XueQing Li, Tony Karlsborn, Mattias Bood, Anders Dahl&#233;n, Constanze Hilgendorf, Deepak Kumar Bhatt. <italic toggle="yes">Conducted experiments</italic>: Jelena Lovri&#263;, Jingjing Yan, XueQing Li, Mattias Bood. <italic toggle="yes">Performed data analysis</italic>: Jelena Lovri&#263;, XueQing Li. <italic toggle="yes">Wrote or contributed to the writing of the manuscript</italic>: Jelena Lovri&#263;, Jingjing Yan, XueQing Li, Tony Karlsborn, Mattias Bood, Anders Dahl&#233;n, Constanze Hilgendorf, Deepak Kumar Bhatt.</p></sec><sec sec-type="COI-statement" id="prp270096-sec-0808"><title>Conflicts of Interest</title><p>Jelena Lovri&#263;, Jingjing Yan, XueQing Li, Tony Karlsborn, Mattias Bood, Anders Dahl&#233;n, Constanze Hilgendorf, Deepak Kumar Bhatt are employees of AstraZeneca and may hold stock in AstraZeneca.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="prp270096-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PRP2-13-e70096-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="prp270096-sec-0019"><title>Acknowledgments</title><p>We acknowledge the authors of the Excel tool for ASO mass calculation (Ionis Pharmaceuticals).</p></ack><sec sec-type="data-availability" id="prp270096-sec-0021"><title>Data Availability Statement</title><p>Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure" ext-link-type="uri" specific-use="software is-supplemented-by">https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ext-link>.</p></sec><ref-list content-type="cited-references" id="prp270096-bibl-0001"><title>References</title><ref id="prp270096-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="prp270096-cit-0001"><string-name name-style="western"><given-names>A. M.</given-names><surname>Belikova</surname></string-name>, <string-name name-style="western"><given-names>V. F.</given-names><surname>Zarytova</surname></string-name>, and <string-name name-style="western"><given-names>N. I.</given-names><surname>Grineva</surname></string-name>, &#8220;<article-title>Synthesis of Ribonucleosides and Diribonucleoside Phosphates Containing 2&#8208;Chloro&#8208;Ethylamine and Nitrogen Mustard Residues</article-title>,&#8221; <source>Tetrahedron Letters</source><volume>8</volume> (<year>1967</year>): <fpage>3557</fpage>&#8211;<lpage>3562</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0040-4039(01)89794-x</pub-id><pub-id pub-id-type="pmid">6073336</pub-id></mixed-citation></ref><ref id="prp270096-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="prp270096-cit-0002"><string-name name-style="western"><given-names>B. M.</given-names><surname>Paterson</surname></string-name>, <string-name name-style="western"><given-names>B. E.</given-names><surname>Roberts</surname></string-name>, and <string-name name-style="western"><given-names>E. L.</given-names><surname>Kuff</surname></string-name>, &#8220;<article-title>Structural Gene Identification and Mapping by DNA&#8208;mRNA Hybrid&#8208;Arrested Cell&#8208;Free Translation</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>74</volume> (<year>1977</year>): <fpage>4370</fpage>&#8211;<lpage>4374</lpage>.<pub-id pub-id-type="pmid">270678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.74.10.4370</pub-id><pub-id pub-id-type="pmcid">PMC431943</pub-id></mixed-citation></ref><ref id="prp270096-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="prp270096-cit-0003"><string-name name-style="western"><given-names>P. C.</given-names><surname>Zamecnik</surname></string-name> and <string-name name-style="western"><given-names>M. L.</given-names><surname>Stephenson</surname></string-name>, &#8220;<article-title>Inhibition of Rous Sarcoma Virus Replication and Cell Transformation by a Specific Oligodeoxynucleotide</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>75</volume> (<year>1978</year>): <fpage>280</fpage>&#8211;<lpage>284</lpage>.<pub-id pub-id-type="pmid">75545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.75.1.280</pub-id><pub-id pub-id-type="pmcid">PMC411230</pub-id></mixed-citation></ref><ref id="prp270096-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="prp270096-cit-0004"><string-name name-style="western"><given-names>J. M.</given-names><surname>Migliorati</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration&#8208;Approved Antisense Oligonucleotide Drugs</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>50</volume> (<year>2022</year>): <fpage>888</fpage>&#8211;<lpage>897</lpage>.<pub-id pub-id-type="pmid">35221287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.121.000417</pub-id><pub-id pub-id-type="pmcid">PMC11022858</pub-id></mixed-citation></ref><ref id="prp270096-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="prp270096-cit-0005"><string-name name-style="western"><given-names>H.</given-names><surname>Stein</surname></string-name> and <string-name name-style="western"><given-names>P.</given-names><surname>Hausen</surname></string-name>, &#8220;<article-title>Enzyme From Calf Thymus Degrading the RNA Moiety of DNA&#8208;RNA Hybrids: Effect on DNA&#8208;Dependent RNA Polymerase</article-title>,&#8221; <source>Science</source><volume>166</volume> (<year>1969</year>): <fpage>393</fpage>&#8211;<lpage>395</lpage>.<pub-id pub-id-type="pmid">5812039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.166.3903.393</pub-id></mixed-citation></ref><ref id="prp270096-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="prp270096-cit-0006"><string-name name-style="western"><given-names>H.</given-names><surname>Donis&#8208;Keller</surname></string-name>, &#8220;<article-title>Site Specific Enzymatic Cleavage of RNA</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>7</volume> (<year>1979</year>): <fpage>179</fpage>&#8211;<lpage>192</lpage>.<pub-id pub-id-type="pmid">386279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/7.1.179</pub-id><pub-id pub-id-type="pmcid">PMC328004</pub-id></mixed-citation></ref><ref id="prp270096-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="prp270096-cit-0007"><string-name name-style="western"><given-names>C.</given-names><surname>Cazenave</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Chevrier</surname></string-name>, <string-name name-style="western"><given-names>N. T.</given-names><surname>Thuong</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>H&#233;l&#232;ne</surname></string-name>, &#8220;<article-title>Rate of Degradation of [&#945;]&#8208; and [&#946;]&#8208;Oligodeoxynucleotides in Xenopus Oocytes. Implications for Anti&#8208;Messenger Strategies</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>15</volume> (<year>1987</year>): <fpage>10507</fpage>&#8211;<lpage>10521</lpage>.<pub-id pub-id-type="pmid">2447563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/15.24.10507</pub-id><pub-id pub-id-type="pmcid">PMC339959</pub-id></mixed-citation></ref><ref id="prp270096-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="prp270096-cit-0008"><string-name name-style="western"><given-names>D. M.</given-names><surname>Tidd</surname></string-name> and <string-name name-style="western"><given-names>H. M.</given-names><surname>Warenius</surname></string-name>, &#8220;<article-title>Partial Protection of Oncogene, Anti&#8208;Sense Oligodeoxynucleotides Against Serum Nuclease Degradation Using Terminal Methylphosphonate Groups</article-title>,&#8221; <source>British Journal of Cancer</source><volume>60</volume> (<year>1989</year>): <fpage>343</fpage>&#8211;<lpage>350</lpage>.<pub-id pub-id-type="pmid">2551358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.1989.283</pub-id><pub-id pub-id-type="pmcid">PMC2247198</pub-id></mixed-citation></ref><ref id="prp270096-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="prp270096-cit-0009"><string-name name-style="western"><given-names>T. M.</given-names><surname>Woolf</surname></string-name>, <string-name name-style="western"><given-names>C. G. B.</given-names><surname>Jennings</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Rebagliati</surname></string-name>, and <string-name name-style="western"><given-names>D. A.</given-names><surname>Melton</surname></string-name>, &#8220;<article-title>The Stability, Toxicity and Effectiveness of Unmodified and Phosphorothioate Antisense Oligodeoxynucleotides in Xenopus Oocytes and Embryos</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>18</volume> (<year>1990</year>): <fpage>1763</fpage>&#8211;<lpage>1769</lpage>.<pub-id pub-id-type="pmid">1692405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/18.7.1763</pub-id><pub-id pub-id-type="pmcid">PMC330594</pub-id></mixed-citation></ref><ref id="prp270096-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="prp270096-cit-0010"><string-name name-style="western"><given-names>J.&#8208;P.</given-names><surname>Shaw</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kent</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Bird</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Fishback</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Froehler</surname></string-name>, &#8220;<article-title>Modified Deoxyoligonucleotides Stable to Exonuclease Degradation in Serum</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>19</volume> (<year>1991</year>): <fpage>747</fpage>&#8211;<lpage>750</lpage>.<pub-id pub-id-type="pmid">1850122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/19.4.747</pub-id><pub-id pub-id-type="pmcid">PMC333706</pub-id></mixed-citation></ref><ref id="prp270096-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="prp270096-cit-0011"><string-name name-style="western"><given-names>S. M.</given-names><surname>Hammond</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Aartsma&#8208;Rus</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Alves</surname></string-name>, et&#160;al., &#8220;<article-title>Delivery of Oligonucleotide&#8208;Based Therapeutics: Challenges and Opportunities</article-title>,&#8221; <source>EMBO Molecular Medicine</source><volume>13</volume> (<year>2021</year>): <elocation-id>e13243</elocation-id>.<pub-id pub-id-type="pmid">33821570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.202013243</pub-id><pub-id pub-id-type="pmcid">PMC8033518</pub-id></mixed-citation></ref><ref id="prp270096-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="prp270096-cit-0012"><string-name name-style="western"><given-names>F.</given-names><surname>Eckstein</surname></string-name>, &#8220;<article-title>Nucleoside Phosphorothioates</article-title>,&#8221; <source>Journal of the American Chemical Society</source><volume>88</volume> (<year>1966</year>): <fpage>4292</fpage>&#8211;<lpage>4294</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja00718a039</pub-id><pub-id pub-id-type="pmid">4316997</pub-id></mixed-citation></ref><ref id="prp270096-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="prp270096-cit-0013"><string-name name-style="western"><given-names>S. T.</given-names><surname>Crooke</surname></string-name>, <string-name name-style="western"><given-names>T. A.</given-names><surname>Vickers</surname></string-name>, and <string-name name-style="western"><given-names>X. H.</given-names><surname>Liang</surname></string-name>, &#8220;<article-title>Phosphorothioate Modified Oligonucleotide&#8208;Protein Interactions</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>48</volume> (<year>2020</year>): <fpage>5235</fpage>&#8211;<lpage>5253</lpage>.<pub-id pub-id-type="pmid">32356888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkaa299</pub-id><pub-id pub-id-type="pmcid">PMC7261153</pub-id></mixed-citation></ref><ref id="prp270096-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="prp270096-cit-0014"><string-name name-style="western"><given-names>T. C.</given-names><surname>Roberts</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Langer</surname></string-name>, and <string-name name-style="western"><given-names>M. J. A.</given-names><surname>Wood</surname></string-name>, &#8220;<article-title>Advances in Oligonucleotide Drug Delivery</article-title>,&#8221; <source>Nature Reviews Drug Discovery</source><volume>19</volume> (<year>2020</year>): <fpage>673</fpage>&#8211;<lpage>694</lpage>.<pub-id pub-id-type="pmid">32782413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-020-0075-7</pub-id><pub-id pub-id-type="pmcid">PMC7419031</pub-id></mixed-citation></ref><ref id="prp270096-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="prp270096-cit-0015"><string-name name-style="western"><given-names>C.</given-names><surname>Wahlestedt</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Salmi</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Good</surname></string-name>, et&#160;al., &#8220;<article-title>Potent and Nontoxic Antisense Oligonucleotides Containing Locked Nucleic Acids</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>97</volume> (<year>2000</year>): <fpage>5633</fpage>&#8211;<lpage>5638</lpage>.<pub-id pub-id-type="pmid">10805816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.97.10.5633</pub-id><pub-id pub-id-type="pmcid">PMC25880</pub-id></mixed-citation></ref><ref id="prp270096-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="prp270096-cit-0016"><string-name name-style="western"><given-names>K.</given-names><surname>Morita</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Hasegawa</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Kaneko</surname></string-name>, et&#160;al., &#8220;<article-title>2&#8242;&#8208;O,4&#8242;&#8208;C&#8208;Ethylene&#8208;Bridged Nucleic Acids (ENA): Highly Nuclease&#8208;Resistant and Thermodynamically Stable Oligonucleotides for Antisense Drug</article-title>,&#8221; <source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>12</volume> (<year>2002</year>): <fpage>73</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">11738576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0960-894x(01)00683-7</pub-id></mixed-citation></ref><ref id="prp270096-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="prp270096-cit-0017"><string-name name-style="western"><given-names>W.</given-names><surname>Shen</surname></string-name>, <string-name name-style="western"><given-names>C. L.</given-names><surname>De Hoyos</surname></string-name>, <string-name name-style="western"><given-names>M. T.</given-names><surname>Migawa</surname></string-name>, et&#160;al., &#8220;<article-title>Chemical Modification of PS&#8208;ASO Therapeutics Reduces Cellular Protein&#8208;Binding and Improves the Therapeutic Index</article-title>,&#8221; <source>Nature Biotechnology</source><volume>37</volume>, no. <issue>6</issue> (<year>2019</year>): <fpage>640</fpage>&#8211;<lpage>650</lpage>, <pub-id pub-id-type="doi">10.1038/s41587-019-0106-2</pub-id>.<pub-id pub-id-type="pmid">31036929</pub-id></mixed-citation></ref><ref id="prp270096-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="prp270096-cit-0018"><string-name name-style="western"><given-names>A. J.</given-names><surname>Pollak</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>T. A.</given-names><surname>Vickers</surname></string-name>, <string-name name-style="western"><given-names>I. J.</given-names><surname>Huggins</surname></string-name>, <string-name name-style="western"><given-names>X.&#8208;H.</given-names><surname>Liang</surname></string-name>, and <string-name name-style="western"><given-names>S. T.</given-names><surname>Crooke</surname></string-name>, &#8220;<article-title>Insights Into Innate Immune Activation via PS&#8208;ASO&#8208;Protein&#8208;TLR9 Interactions</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>50</volume> (<year>2022</year>): <fpage>8107</fpage>&#8211;<lpage>8126</lpage>.<pub-id pub-id-type="pmid">35848907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkac618</pub-id><pub-id pub-id-type="pmcid">PMC9371907</pub-id></mixed-citation></ref><ref id="prp270096-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="prp270096-cit-0019"><string-name name-style="western"><given-names>R.</given-names><surname>Stanton</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sciabola</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Salatto</surname></string-name>, et&#160;al., &#8220;<article-title>Chemical Modification Study of Antisense Gapmers</article-title>,&#8221; <source>Nucleic Acid Therapeutics</source><volume>22</volume> (<year>2012</year>): <fpage>344</fpage>&#8211;<lpage>359</lpage>.<pub-id pub-id-type="pmid">22852836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/nat.2012.0366</pub-id></mixed-citation></ref><ref id="prp270096-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="prp270096-cit-0020"><string-name name-style="western"><given-names>B. P.</given-names><surname>Monia</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Johnston</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Sasmor</surname></string-name>, and <string-name name-style="western"><given-names>L. L.</given-names><surname>Cummins</surname></string-name>, &#8220;<article-title>Nuclease Resistance and Activity of Oligonucleotides Targeted to ha&#8208;Ras*</article-title>,&#8221; <source>Journal of Biological Chemistry</source><volume>271</volume> (<year>1996</year>): <fpage>14533</fpage>&#8211;<lpage>14540</lpage>.<pub-id pub-id-type="pmid">8662854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.271.24.14533</pub-id></mixed-citation></ref><ref id="prp270096-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="prp270096-cit-0021"><string-name name-style="western"><given-names>J.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>N. M.</given-names><surname>El Zahar</surname></string-name>, and <string-name name-style="western"><given-names>M. G.</given-names><surname>Bartlett</surname></string-name>, &#8220;<article-title>In Vitro Metabolism of 2&#8242;&#8208;Ribose Unmodified and Modified Phosphorothioate Oligonucleotide Therapeutics Using Liquid Chromatography Mass Spectrometry</article-title>,&#8221; <source>Biomedical Chromatography</source><volume>34</volume> (<year>2020</year>): <elocation-id>e4839</elocation-id>.<pub-id pub-id-type="pmid">32246854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bmc.4839</pub-id></mixed-citation></ref><ref id="prp270096-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="prp270096-cit-0022"><string-name name-style="western"><given-names>A.</given-names><surname>Hofmeister</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Jahn&#8208;Hofmann</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Brunner</surname></string-name>, et&#160;al., &#8220;<article-title>Syntheses of Morpholine&#8208;Based Nucleotide Analogs for Hepatic siRNA Targeting and Stabilization</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume> (<year>2021</year>): <fpage>6838</fpage>&#8211;<lpage>6855</lpage>.<pub-id pub-id-type="pmid">33950677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c00144</pub-id></mixed-citation></ref><ref id="prp270096-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="prp270096-cit-0023"><string-name name-style="western"><given-names>W. E.</given-names><surname>Razzell</surname></string-name> and <string-name name-style="western"><given-names>H. G.</given-names><surname>Khorana</surname></string-name>, &#8220;<article-title>Studies on Polynucleotides. III. Enzymic Degradation; Substrate Specificity and Properties of Snake Venom Phosphodiesterase</article-title>,&#8221; <source>Journal of Biological Chemistry</source><volume>234</volume> (<year>1959</year>): <fpage>2105</fpage>&#8211;<lpage>2113</lpage>.<pub-id pub-id-type="pmid">13673021</pub-id></mixed-citation></ref><ref id="prp270096-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="prp270096-cit-0024"><string-name name-style="western"><given-names>P. M.</given-names><surname>Burgers</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Eckstein</surname></string-name>, and <string-name name-style="western"><given-names>D. H.</given-names><surname>Hunneman</surname></string-name>, &#8220;<article-title>Stereochemistry of Hydrolysis by Snake Venom Phosphodiesterase</article-title>,&#8221; <source>Journal of Biological Chemistry</source><volume>254</volume> (<year>1979</year>): <fpage>7476</fpage>&#8211;<lpage>7478</lpage>.<pub-id pub-id-type="pmid">224029</pub-id></mixed-citation></ref><ref id="prp270096-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="prp270096-cit-0025"><string-name name-style="western"><given-names>W.</given-names><surname>Zhou</surname></string-name> and <string-name name-style="western"><given-names>S.</given-names><surname>Agrawal</surname></string-name>, &#8220;<article-title>Mixed&#8208;Backbone Oligonucleotides as Second&#8208;Generation Antisense Agents With Reduced Phosphorothioate&#8208;Related Side Effects</article-title>,&#8221; <source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>8</volume> (<year>1998</year>): <fpage>3269</fpage>&#8211;<lpage>3274</lpage>.<pub-id pub-id-type="pmid">9873716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0960-894x(98)00591-5</pub-id></mixed-citation></ref><ref id="prp270096-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="prp270096-cit-0026"><string-name name-style="western"><given-names>M.</given-names><surname>Meng</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Schmidtgall</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Ducho</surname></string-name>, &#8220;<article-title>Enhanced Stability of DNA Oligonucleotides With Partially Zwitterionic Backbone Structures in Biological Media</article-title>,&#8221; <source>Molecules</source><volume>23</volume> (<year>2018</year>): <fpage>2941</fpage>.<pub-id pub-id-type="pmid">30423832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules23112941</pub-id><pub-id pub-id-type="pmcid">PMC6278555</pub-id></mixed-citation></ref><ref id="prp270096-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="prp270096-cit-0027"><string-name name-style="western"><given-names>P. S.</given-names><surname>Eder</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>DeVine</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Dagle</surname></string-name>, and <string-name name-style="western"><given-names>J. A.</given-names><surname>Walder</surname></string-name>, &#8220;<article-title>Substrate Specificity and Kinetics of Degradation of Antisense Oligonucleotides by a 3&#8242; Exonuclease in Plasma</article-title>,&#8221; <source>Antisense Research and Development</source><volume>1</volume> (<year>1991</year>): <fpage>141</fpage>&#8211;<lpage>151</lpage>.<pub-id pub-id-type="pmid">1841656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/ard.1991.1.141</pub-id></mixed-citation></ref><ref id="prp270096-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="prp270096-cit-0028"><string-name name-style="western"><given-names>G. D.</given-names><surname>Hoke</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Draper</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Freier</surname></string-name>, et&#160;al., &#8220;<article-title>Effects of Phosphorothioate Capping on Antisense Oligonucleotide Stability, Hybridization and Antiviral Efficacy Versus Herpes Simplex Virus Infection</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>19</volume> (<year>1991</year>): <fpage>5743</fpage>&#8211;<lpage>5748</lpage>.<pub-id pub-id-type="pmid">1658742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/19.20.5743</pub-id><pub-id pub-id-type="pmcid">PMC328985</pub-id></mixed-citation></ref><ref id="prp270096-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="prp270096-cit-0029"><string-name name-style="western"><given-names>K. E.</given-names><surname>Lundin</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>H&#248;jland</surname></string-name>, <string-name name-style="western"><given-names>B. R.</given-names><surname>Hansen</surname></string-name>, et&#160;al., &#8220;<article-title>Biological Activity and Biotechnological Aspects of Locked Nucleic Acids</article-title>,&#8221; <source>Advances in Genetics</source><volume>82</volume> (<year>2013</year>): <fpage>47</fpage>&#8211;<lpage>107</lpage>.<pub-id pub-id-type="pmid">23721720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-407676-1.00002-0</pub-id></mixed-citation></ref><ref id="prp270096-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="prp270096-cit-0030"><string-name name-style="western"><given-names>R. M.</given-names><surname>Crooke</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Graham</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Martin</surname></string-name>, <string-name name-style="western"><given-names>K. M.</given-names><surname>Lemonidis</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Wyrzykiewiecz</surname></string-name>, and <string-name name-style="western"><given-names>L. L.</given-names><surname>Cummins</surname></string-name>, &#8220;<article-title>Metabolism of Antisense Oligonucleotides in Rat Liver Homogenates</article-title>,&#8221; <source>Journal of Pharmacology and Experimental Therapeutics</source><volume>292</volume> (<year>2000</year>): <fpage>140</fpage>&#8211;<lpage>149</lpage>.<pub-id pub-id-type="pmid">10604941</pub-id></mixed-citation></ref><ref id="prp270096-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="prp270096-cit-0031"><string-name name-style="western"><given-names>L. E.</given-names><surname>Xodo</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Alunni&#8208;Fabbroni</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Manzini</surname></string-name>, &#8220;<article-title>Effect of 5&#8208;Methylcytosine on the Structure and Stability of DNA. Formation of Triple&#8208;Stranded Concatenamers by Overlapping Oligonucleotides</article-title>,&#8221; <source>Journal of Biomolecular Structure &amp; Dynamics</source><volume>11</volume> (<year>1994</year>): <fpage>703</fpage>&#8211;<lpage>720</lpage>.<pub-id pub-id-type="pmid">8204209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.1994.10508027</pub-id></mixed-citation></ref><ref id="prp270096-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="prp270096-cit-0032"><string-name name-style="western"><given-names>S.</given-names><surname>Blanco</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Dietmann</surname></string-name>, <string-name name-style="western"><given-names>J. V.</given-names><surname>Flores</surname></string-name>, et&#160;al., &#8220;<article-title>Aberrant Methylation of tRNAs Links Cellular Stress to Neuro&#8208;Developmental Disorders</article-title>,&#8221; <source>EMBO Journal</source><volume>33</volume> (<year>2014</year>): <fpage>2020</fpage>&#8211;<lpage>2039</lpage>.<pub-id pub-id-type="pmid">25063673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.201489282</pub-id><pub-id pub-id-type="pmcid">PMC4195770</pub-id></mixed-citation></ref><ref id="prp270096-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="prp270096-cit-0033"><string-name name-style="western"><given-names>W. B.</given-names><surname>Wan</surname></string-name> and <string-name name-style="western"><given-names>P. P.</given-names><surname>Seth</surname></string-name>, &#8220;<article-title>The Medicinal Chemistry of Therapeutic Oligonucleotides</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>59</volume> (<year>2016</year>): <fpage>9645</fpage>&#8211;<lpage>9667</lpage>.<pub-id pub-id-type="pmid">27434100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.6b00551</pub-id></mixed-citation></ref><ref id="prp270096-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="prp270096-cit-0034"><string-name name-style="western"><given-names>D. R.</given-names><surname>Scoles</surname></string-name>, <string-name name-style="western"><given-names>E. V.</given-names><surname>Minikel</surname></string-name>, and <string-name name-style="western"><given-names>S. M.</given-names><surname>Pulst</surname></string-name>, &#8220;<article-title>Antisense Oligonucleotides: A Primer</article-title>,&#8221; <source>Neurology Genetics</source><volume>5</volume>, no. <issue>2</issue> (<year>2019</year>): <elocation-id>e323</elocation-id>, <pub-id pub-id-type="doi">10.1212/NXG.0000000000000323</pub-id>.<pub-id pub-id-type="pmid">31119194</pub-id><pub-id pub-id-type="pmcid">PMC6501637</pub-id></mixed-citation></ref><ref id="prp270096-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="prp270096-cit-0035"><string-name name-style="western"><given-names>C.</given-names><surname>Rausch</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>C. S.</given-names><surname>Casas&#8208;Delucchi</surname></string-name>, et&#160;al., &#8220;<article-title>Cytosine Base Modifications Regulate DNA Duplex Stability and Metabolism</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>49</volume> (<year>2021</year>): <fpage>12870</fpage>&#8211;<lpage>12894</lpage>.<pub-id pub-id-type="pmid">34133727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkab509</pub-id><pub-id pub-id-type="pmcid">PMC8682791</pub-id></mixed-citation></ref><ref id="prp270096-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="prp270096-cit-0036"><string-name name-style="western"><given-names>T. T.</given-names><surname>Nikiforov</surname></string-name>, <string-name name-style="western"><given-names>R. B.</given-names><surname>Rendle</surname></string-name>, <string-name name-style="western"><given-names>M. L.</given-names><surname>Kotewicz</surname></string-name>, and <string-name name-style="western"><given-names>Y. H.</given-names><surname>Rogers</surname></string-name>, &#8220;<article-title>The Use of Phosphorothioate Primers and Exonuclease Hydrolysis for the Preparation of Single&#8208;Stranded PCR Products and Their Detection by Solid&#8208;Phase Hybridization</article-title>,&#8221; <source>PCR Methods and Applications</source><volume>3</volume> (<year>1994</year>): <fpage>285</fpage>&#8211;<lpage>291</lpage>.<pub-id pub-id-type="pmid">8038696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gr.3.5.285</pub-id></mixed-citation></ref><ref id="prp270096-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="prp270096-cit-0037"><string-name name-style="western"><given-names>A. E.</given-names><surname>Pritchard</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Kowalski</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Laskowski</surname>, <suffix>Sr.</suffix></string-name>, &#8220;<article-title>An Endonuclease Activity of Venom Phosphodiesterase Specific for Single&#8208;Stranded and Superhelical DNA</article-title>,&#8221; <source>Journal of Biological Chemistry</source><volume>252</volume> (<year>1977</year>): <fpage>8652</fpage>&#8211;<lpage>8659</lpage>.<pub-id pub-id-type="pmid">200616</pub-id></mixed-citation></ref><ref id="prp270096-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="prp270096-cit-0038"><string-name name-style="western"><given-names>M.</given-names><surname>Napirei</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ludwig</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Mezrhab</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kl&#246;ckl</surname></string-name>, and <string-name name-style="western"><given-names>H. G.</given-names><surname>Mannherz</surname></string-name>, &#8220;<article-title>Murine Serum Nucleases&#8212;Contrasting Effects of Plasmin and Heparin on the Activities of DNase1 and DNase1&#8208;like3 (DNase1l3)</article-title>,&#8221; <source>FEBS Journal</source><volume>276</volume> (<year>2009</year>): <fpage>1059</fpage>&#8211;<lpage>1073</lpage>.<pub-id pub-id-type="pmid">19154352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-4658.2008.06849.x</pub-id></mixed-citation></ref><ref id="prp270096-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="prp270096-cit-0039"><string-name name-style="western"><given-names>X.&#8208;Q.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Elebring</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Dahl&#233;n</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Weidolf</surname></string-name>, &#8220;<article-title>In Vivo Metabolite Profiles of a GalNAc Conjugated Antisense Oligonucleotide AZD8233 Using Liquid Hromatography&#8208;High Resolution Mass Spectrometry: A Cross Species Comparison in Animals and Humans</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>51</volume> (<year>2023</year>): <fpage>1350</fpage>&#8211;<lpage>1361</lpage>.<pub-id pub-id-type="pmid">37429729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.123.001370</pub-id></mixed-citation></ref><ref id="prp270096-bib-0040"><label>40</label><mixed-citation publication-type="miscellaneous" id="prp270096-cit-0040"><collab collab-type="authors">FDA</collab>
, <article-title>&#8220;FDA Draft Guidance for Nonclincial Safety Assessment of Oligonucleotide&#8208;Based Therapeutics,&#8221;</article-title> 2024, accessed November 18, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/183496/download" ext-link-type="uri">https://www.fda.gov/media/183496/download</ext-link>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>